Defense Technical Information Center Compilation Part Notice
|
|
- Jared Stokes
- 5 years ago
- Views:
Transcription
1 UNCLASSIFIED Defense Technical Information Center Compilation Part Notice ADPO TITLE: Lipid Lowering Agents Aeromedical Concerns DISTRIBUTION: Approved for public release, distribution unlimited This paper is part of the following report: TITLE: Medication for Military Aircrew: Current Use, Issues, and Strategies for Expanded Options [les medicaments pour les equipaes militaires: Consommation actuelle, questions et strategies pour des options elargies] To order the complete compilation report, use: ADA The component part is provided here to allow users access to individually authored sections f proceedings, annals, symposia, etc. However, the component should be considered within [he context of the overall compilation report and not as a stand-alone technical report. The following component part numbers comprise the compilation report: ADPO11041 thru ADP UNCLASSIFIED
2 15 Lipid Lowering Agents Aeromedical Concerns Themis Eliopoulos, M.D 251 HAF General Hospital - Cardiology Dept Pan Kanellopoulou 3 Cholargos, 11525, Athens Greece The Problem of Hyperlipidemia in Military Dietary and Drug Therapy Aviators Dietary and drug therapy can lower cholesterol and Hyperlipidemia is one of the major risk factors for prevent coronary heart disease. In particular, LDL coronary heart disease, a disease which, after a long cholesterol is strongly associated with atherogenesis asymptomatic period, may without warning cause and is the usual target for intervention. The sudden incapacitation due to angina, myocardial indications for initiating dietary and drug therapy, infarction or death. Hyperlipidemia is fairly and the suggested target levels, are listed in Tables common in military aviators, ranging from 30-2 and 3.3 However, it must be emphasized that 68.5% in NATO countries.' In a survey among correction of weight, aerobic exercise, and cessation Greek fighter pilots, 10% had cholesterol levels of smoking should be considered part of the overall over 300 mg/dli. strategy. Lipoprotein Levels Dietary measures should be pursued for at least 3-6 months before contemplating lipid lowering drugs. Cholesterol measurement is best performed in On average, around 5% reduction in LDL hospital chemical pathology departments after a cholesterol is achievable with dietary therapy. 9 fasting state (12-14 hour overnight fast) to allow Drug therapy should be reserved for those military concomitant measurement of triglyceride levels, aviators at high risk for CHD, in the second and Provided triglyceride levels are < 400 mg/dl (4.5 third priorities, where diet and healthy lifestyle mmol /L), LDL is calculated according to the measures have failed to achieve target levels. Friedewald formula. 3 LDL= Total Cholesterol - HDL- TG/5 Major Classes of Lipid Lowering Drugs The current definitions of cholesterol and lipo- The major classes of lipid lowering drugs are: protein levels are listed in Table 1. a. Bile acid sequestrants (cholestyramine, Risk Factors for Cardiovascular disease colestipol) b. Fibric acid derivatives (gemfibrozil, The major risk factors for cardiovascular disease fenofibrate, etc.) are: c. HMG-CoA reductase inhibitors, commonly a. age (male >45yr, female >55yr or premature referred to as "statins" (lovastatin, pravastatin, menopause simvastatin, fluvastatin, atorvastatin) b. family history of premature CHD (first degree d. Others (nicotinic acid, probucol) male relative <55, first degree female relative < 65) Bile acid sequestrants: The bile acid sequestrants c. n ccurrently available include cholestyramine and c. current cigarette smoking colestipol. Cholestyramine is dispensed in packets d. hypertension (BP>140/90 mm Hg, or taking or scoops containing 4g of the active agent. The antihypertensive medication) usual dosage ranges from 16 to 32g daily, taken e. low HDL cholesterol (<35 mg/dl) with fluids in divided doses. Colestipol is f. diabetes mellitus dispensed in 5g packets. The usual dosage ranges from 15 to 30g daily in divided doses. These agents
3 16 are not absorbed. The major side effects are inhibitors may have clinical implications that are constipation and difficulty in ingesting the agents particularly relevant to military aviators. because of their bulk. Oddly enough, constipation tends to be a problem at lower dosages, and to The lipid lowering effect of statins is achieved by decrease as the dosage is increased. Occasionally, competitive and reversible inhibition of HMG-CoA cholestyramine can increase plasma triglyceride reductase in hepatocytes, which induces a reduction levels. Bile acid sequestrants have been used for in intracellular stores of cholesterol. As a conseyears as the drug of choice for military aviators, and quence of the decline in cholesterol levels, there is their long-term safety is well established, up-regulation of LDL receptors on hepatocyte Compliance has usually been the major problem, membranes, resulting in enhanced receptoreven in clinical trials, as resins are not only mediated catabolism and clearance of atherogenic inconvenient to take but also produce gastro- LDL-cholesterol. Thus the liver is the primary site intestinal side effects. Because of the difficulty of action of statins. Administration of statins in the with compliance, resins may not be the optimal evening is associated with a greater lipid-lowering agent for use by aircrew. effect than that seen with morning administration. This is almost certainly due to the increased Fibric acid derivatives: The most commonly used nocturnal biosynthesis of cholesterol that occurs in is gemfibrozil, which has been shown to decrease humans. Clinically, the most important adverse coronary mortality. Gemfibrozil can be used as events associated with HMG-CoA reductase first-line therapy in persons with concomitant high inhibitors are myopathy and increases in hepatic triglyceride and low HDL levels. Dosage is 600mg transaminase levels. Myopathy, defined as twice a day. Fenofibrate, ciprofibrate and muscular aching and weakness accompanied by a bezafibrate are also used. They can reduce LDL by >10-fold elevation in CPK, is uncommon, occurring 20-30%, increase HDL by 10-15%, and reduce in <0.10% of patients in clinical trials of pravastatin.8 triglycerides by 40-60%. The most common side If not recognized, however, myopathy can proceed effect is gastrointestinal intolerance; myalgia is a to rhabdomyolysis and acute renal failure. It is rare complication. Gemfibrozil has also been generally recommended that HMG-CoA reductase associated with increased lithogenicity. inhibitor therapy be discontinued in patients developing markedly elevated CPK levels, or in HMG-CoA Reductase Inhibitors: The statins are those with symptoms suspicious for myopathy. the most potent drugs available for reducing plasma concentration of LDL cholesterol. Statins reduce In common with other HMG-CoA reductase plasma LDL cholesterol by 30-40%, decrease inhibitors, as well as other lipid-lowering drugs, plasma triglyceride by 10-30%, and increase HDL biochemical abnormalities of liver function may cholesterol by 2-15%. Many statins (pravastatin, occur with pravastatin therapy. Such increases in atorvastatin, fluvastatin, lovastatin, and simvastatin) serum liver enzyme levels associated with have been developed for clinical use and are now pravastatin therapy routinely resolve on drug available in Europe and the United States. discontinuation, and are usually asymptomatic. In the WOSCOPS study, elevated SGOT and SGPT Simvastatin and lovastatin are administered as levels (> 3 times upper limit of normal) were lactones, and conversion to the active open acid present in 0.78% and 0.48% of 3302 pravastatin and occurs in the liver. In contrast, pravastatin is 3293 placebo-treated patients, respectively. 8 administered as a sodium salt of the open acid. Simvastatin is fat soluble, while pravastatin is water Clinical Experience in Primary Prevention of soluble and does not appear to cross the blood-brain CAD with Lipid Lowering Agents barrier. Pravastatin has been shown to be minimally detectable in the cerebrospinal fluid of Five randomized, placebo-controlled trials have healthy volunteers, whereas lovastatin was present examined pharmacologic lipid-lowering therapy for at concentrations that could have a pharmacologic primary prevention. The three early trials (World effect. 6 The inability of pravastatin to penetrate Health Organization study with clofibrate, LRCinto cerebrospinal fluid has been attributed to its CPPT with cholestyramine, and Helsinki Heart hydrophilicity and low affinity for the transport Study with gemfibrozil) showed a significant mechanism of the blood-brain barrier. 7 The CNS reduction in the risk of developing coronary penetration of lipophilic HMG-CoA reductase events.'" "
4 The two latest trials, WOSCOPS, using pravastatin, pravastatin, in which both showed an increase in and AFCAPS/TexCAPS, using lovastatin, clearly wakefulness during the latter part of the night, but demonstrated reduction (31% and 37%, respec- neither drug appeared to affect subjective sleep tively) in the risk of cardiac death and nonfatal assessment or performance.17 myocardial infarction with statin therapy for primary prevention.8,1 2 These data show that lipid- Conclusion lowering therapy, particularly with statins, can be effective in preventing cardiac events in patients The basis for the usual therapy of hyperlipidemias, without a previous diagnosis of coronary heart apart from severe and hereditary types, is strict disease. To answer the question of cost-effective- dietary modification. Careful attention to all other ness for primary prevention we must compare the coronary risk factors is essential. It is clear from number of patients needed to treat in order to epidemiologic studies that, even in the "normal" prevent one CHD death or nonfatal MI. Among range of cholesterol, lower values are associated patients enrolled in the primary prevention trial with fewer cardiovascular events, emphasizing the AFCAPS/TexCAPS, 83 patients required treatment virtues of dietary advice for aircrew. Drug therapy to prevent one cardiac event. In the primary can be used when dietary management fails or is prevention trial WOSCOPS, treatment of 40 inappropriate. No ideal lipid-lowering drug has yet patients prevented one cardiac event. As the risk been found. Statins are the most effective lipidprofile becomes more ominous, the cost-effective- lowering agents, and seem to be safe according to ness increases. large trials. Among the statins, the hydrophilic pravastatin has been preferred for use in aircrew, Cholesterol Lowering Therapy and the Central since both in theory and in studies it does not Nervous System appear to affect the central nervous system. Whether the minor disturbances in sleep observed Cholesterol is an important constituent of the with some of the statins is of significance to aircrew central nervous system, which contains about 20% involved in intensive operations is unclear at this of the non-exchangeable pool of cholesterol in the time. body. Thus it is pertinent to consider whether lipid lowering therapy that decreases cholesterol syn- References thesis might also adversely affect CNS functions, including emotional, intellectual and organic 1. AGARD Conference Proceedings 5331SBN functions. This aspect of lipid lowering therapy is particularly relevant to military aviators. 2. IATRIKI EPITHEORISIS ENOPLON Simvastatin and lovastatin, being lipophilic agents, DYNAMEON; Dec1995. have been shown to cross the blood brain barrier, in contrast to the hydrophilic agent pravastatin. This 3. Study Group of European Atherosclerosis Study. CNS penetration of HMG-CoA reductase inhibitors Eur Heart J 1987;8: may also have clinical implications. Lovastatin and simvastatin, but not pravastatin, have been reported 4. Pan, et al. Clin Pharmacol Ther 1990;48: to be associated with sleep disturbance. Also, a recent study1 3 suggested that lovastatin significantly 5. Hunningake, et al. Atherosclerosis affected daytime performance, with divided 1990;85: attention and vigilance worsening, effects that were not observed in the pravastatin group. Neither 6. Triscary, et al. Clin. Neuropharm 1993;16:559- pravastatin nor lovastatin significantly affected 60. nocturnal sleep or daytime sleepiness. Similar results were reported in later studies.1 4 "1 5 However, 7. Tsuji, et al. J Pharm.Exp.Ther 1993;267:1085- in a subsequent comparative study of lovastatin and 90. pravastatin there was no significant effect by either drug on sleep or CNS function, including visual 8. Shepherd, et al. N Engl J Med 1995;333:1301- reaction time, auditory reaction time, verbal 7. learning, embedded figures tests, verbal fluency test, trail making test, or visual memory test Hunninghake DB, et al. N Engl J Med 1993; There are unpublished data about atorvastatin and 328:
5 LRCP. JAMA 1984;251: Vgontzas, et al. Clin Pharm Ther 1991;50(6): Frick MH, et al. N Engl J Med 1987;317: Kostis, et al. Eur Heart Journal Abstr Supl 1994;15:3162; Downs JR, et al. JAMA 1998;279: Turner, et al. Defence Evaluation and Research 13. Richardson, et al. Proceedings of the 9 th Agency, Center for Human Sciences, Farnborough, International Symposium on Atherosclerosis; Oct Hampshire, UK (personal communication) 1991, p Roth, et al. Proceedings of the 9 th International Symposium on Atherosclerosis; Oct 1991, p TABLE 1: Lipoprotein Levels Total Cholesterol Desirable Borderline High LDL Cholesterol Desirable Borderline High risk HDL Cholesterol Low <200mg/dl (5.2mmol/L) mg/dl ( mmol/L) >250mg/dl (6.5mmol/L) <130mg/dl (3.4mmol/L) mg/dl ( mmol/l) >160mg/dl (5mmol/L) <35mg/dl (0.9mmol/L) TABLE 2: Indications for Initiating Dietary Therapy, and the Suggested Target Levels Total Cholesterol (mg/dl) LDL Cholesterol (m2/dl) Initiation Target Initiation Target Priority Subject Cate2ory Level Level Level Level First CHD >200 <200 >100 <100 Second Without CHD, and with 2 or more risk >250 <200 >130 <130 factors, or genetically determined hyperlipidemia Third Without CHD and with fewer than 2 >300 <200 >160 <160 risk factors
6 19 TABLE 3: Indications for Initiating Drug Therapy, and the Suggested Target Levels Total Cholesterol (mg/dl) LDL Cholesterol (midl) Initiation Target Initiation Target Priority Subject Category Level Level Level Level First CHD >200 <200 >130 <100 Second Without CHD, and with 2 or more risk >250 <200 >160 <130 factors, or genetically determined hyperlipidemia Third Without CHD and with fewer than 2 >300 <200 >190 <160 risk factors
7 This page has been deliberately left blank Page intentionnellement blanche
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Guidelines for Screening and Management of Dyslipidemia
PIEDMONT ACCESS TO HEALTH SERVICES, INC. Policy Number: 01-09-021 SUBJECT: Guidelines for Screening and Management of Dyslipidemia EFFECTIVE DATE: 04/2008 REVIEWED/REVISED: 04/12/10, 03/17/2011, 4/10/2012,
More informationCholesterol Management Roy Gandolfi, MD
Cholesterol Management 2017 Roy Gandolfi, MD Goals Interpreting cholesterol guidelines Cholesterol treatment in diabetics Statin use and side effects therapy Reporting- Comparison data among physicians
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Hyperlipidemias. Hyperlipoproteinemias. Hyperlipemia. Hypercholestrolemia. Direct relationship with acute pancreatitis and atherosclerosis Structure Lipoprotein Particles Types
More informationMOLINA HEALTHCARE OF CALIFORNIA
MOLINA HEALTHCARE OF CALIFORNIA HIGH BLOOD CHOLESTEROL IN ADULTS GUIDELINE Molina Healthcare of California has adopted the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel
More information( Diabetes mellitus, DM ) ( Hyperlipidemia ) ( Cardiovascular disease, CVD )
005 6 69-74 40 mg/dl > 50 mg/dl) (00 mg/dl < 00 mg/dl(.6 mmol/l) 30-40% < 70 mg/dl 40 mg/dl 00 9 mg/dl fibric acid derivative niacin statin fibrate statin niacin ( ) ( Diabetes mellitus,
More informationANTIHYPERLIPIDEMIA. Darmawan,dr.,M.Kes,Sp.PD
ANTIHYPERLIPIDEMIA Darmawan,dr.,M.Kes,Sp.PD Plasma lipids consist mostly of lipoproteins Spherical complexes of lipids and specific proteins (apolipoproteins). The clinically important lipoproteins, listed
More informationAntihyperlipidemic drugs
Antihyperlipidemic drugs The clinically important lipoproteins are LDL low density lipoprotein, VLDL very low density lipoprotein, HDL high density lipoprotein. Hyperlipidemia may caused 1. by individual
More informationAntihyperlipidemic Drugs
Antihyperlipidemic Drugs Lipid disorders: Disorders of lipid metabolism are manifest by elevation of the plasma concentrations of the various lipid and lipoprotein fractions (total and LDL cholesterol,
More informationManagement of Post-transplant hyperlipidemia
Management of Post-transplant hyperlipidemia B. Gisella Carranza Leon, MD Assistant Professor of Medicine Lipid Clinic - Vanderbilt Heart and Vascular Institute Division of Diabetes, Endocrinology and
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationnicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck
Scottish Medicines Consortium Resubmission nicotinic acid 375mg, 500mg, 750mg, 1000mg modified release tablet (Niaspan ) No. (93/04) Merck New formulation 6 January 2006 The Scottish Medicines Consortium
More informationHyperlipidemia. Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi
Hyperlipidemia Prepared by : Muhannad Mohammed Supervisor professor : Dr. Ahmed Yahya Dallalbashi Outline The story of lipids Definition of hyperlipidemia Classification of hyperlipidemia Causes of hyperlipidemia
More informationSTATIN UTILIZATION MANAGEMENT CRITERIA
STATIN UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: HMG Co-A Reductase Inhibitors & Combinations Agents which require prior review: Advicor (niacin extended-release/lovastatin) Crestor (rosuvastatin)(5mg,10mg,
More informationAnti Hyperlipidemic Drugs. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Anti Hyperlipidemic Drugs Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Lipoproteins Macromolecular complexes in the blood that transport lipids Apolipoproteins
More informationDYSLIPIDEMIA PHARMACOLOGY. University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
DYSLIPIDEMIA PHARMACOLOGY University of Hawai i Hilo Pre- Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 LEARNING OBJECTIVES Know normal cholesterol levels Understand what the role
More informationPharmacology Challenges: Managing Statin Myalgia
Clinical Case: RM is a 50 year-old African American woman with a past medical history of type diabetes, dyslipidemia, hypertension and peripheral arterial disease. She had been prescribed simvastatin 80
More informationPATIENT INFORMATION. Medicine To Treat: C ardiac Diseases. Lipid-Lowering Medicines. Statins Fibrates Fat Binding Agents Nicotinic Acid Group
PATIENT INFORMATION Medicine To Treat: C ardiac Diseases Lipid-Lowering Medicines Statins Fibrates Fat Binding Agents Nicotinic Acid Group ABOUT YOUR MEDICINE Your doctor has just prescribed for you: Medicine
More informationIn the Know: Canadian Guidelines for Dyslipidemia, 2003
In the Know: Canadian Guidelines for Dyslipidemia, 2003 In his reviews of Canadian dyslipidemia guidelines, Dr. Curnew explores the impact of major trials, the assessment and categories of risk, and both
More informationATP IV: Predicting Guideline Updates
Disclosures ATP IV: Predicting Guideline Updates Daniel M. Riche, Pharm.D., BCPS, CDE Speaker s Bureau Merck Janssen Boehringer-Ingelheim Learning Objectives Describe at least two evidence-based recommendations
More informationCLINICAL IMPORTANCE OF LIPOPROTEINS
25 Hyperlipidemias CLINICAL IMPORTANCE OF LIPOPROTEINS Raised levels of low-density lipoprotein (LDL) cholesterol and low levels of high density lipoprotein (HDL) cholesterol are independent risk factor
More informationLipid Therapy: Statins and Beyond. Ivan Anderson, MD RIHVH Cardiology
Lipid Therapy: Statins and Beyond Ivan Anderson, MD RIHVH Cardiology Outline The cholesterol hypothesis and lipid metabolism The Guidelines 4 Groups that Benefit from Lipid therapy Initiation and monitoring
More informationDyslipidemia in the light of Current Guidelines - Do we change our Practice?
Dyslipidemia in the light of Current Guidelines - Do we change our Practice? Dato Dr. David Chew Soon Ping Senior Consultant Cardiologist Institut Jantung Negara Atherosclerotic Cardiovascular Disease
More informationFibrates. Spotlight on. Fibric acid derivatives (fibrates) have been used. When should I prescribe fibrates? In this article: Andrew s visit
Focus on CME at the University of Alberta Spotlight on By T. K. Lee, MSc (Exp. Medicine), MB, BS, MRCP(UK), ABIM, FRCPC As presented at the Drug Update & Practical Therapeutics Course, November 8, 2002.
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLearning Objectives. Patient Case
Joseph Saseen, Pharm.D., FASHP, FCCP, BCPS Professor and Vice Chair, Department of Clinical Pharmacy University of Colorado Anschutz Medical Campus Learning Objectives Identify the 4 patient populations
More informationIntroduction Hyperlipidemia hyperlipoproteinemia Primary hyperlipidemia (Familial) Secondary hyperlipidemia (Acquired)
Introduction Hyperlipidemia, or hyperlipoproteinemia, is the condition of abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemias are divided in primary and secondary
More informationLipid Guidelines Who, What, and How Low. Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute
Lipid Guidelines Who, What, and How Low Anita Ralstin, MS, CNP Next Step Health Consultant, LLC New Mexico Heart Institute Disclosures! None Objectives! List factors used in screening for dyslipidemia
More informationIn May 2001, the National Cholesterol. Effective Management of Patients With Dyslipidemia REPORT. Robert J. Lipsy, PharmD
REPORT Effective Management of Patients With Dyslipidemia Robert J. Lipsy, PharmD Abstract Coronary heart disease (CHD) is the leading cause of morbidity and mortality in the United States. A direct relationship
More informationRoyal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines Lipid Lowering Therapy for the Prevention of Cardiovascular Disease
Royal Wolverhampton Hospital Adult Lipid Lowering Therapy Guidelines 1 This guideline is intended to assist rational and cost-effective prescribing of lipid regulating medications across both primary and
More informationCopy right protected Page 1
CHOLESTEROL and TGs LOWERING DRUGS Introduction: Fat (lipids) are combinations (esters) of fatty acids plus an alcohol. The two main fats in the body are triglycerides (TGs) and cholesterol Triglycerides
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Adult Certified Nurse Practitioner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationLipid Lowering Drugs. Dr. Alia Shatanawi
Lipid Lowering Drugs Dr. Alia Shatanawi Atherosclerosis A form of arteriosclerosis characterized by the deposition of atheromatous plaques containing cholesterol and lipids on the innermost layer of the
More informationComparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients
Comparison of Original and Generic Atorvastatin for the Treatment of Moderate Dyslipidemic Patients Cardiology Department, Bangkok Metropolitan Medical College and Vajira Hospital, Bangkok, Thailand Abstract
More informationApproach to Dyslipidemia among diabetic patients
Approach to Dyslipidemia among diabetic patients Farzad Hadaegh, MD, Professor of Internal Medicine & Endocrinology Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences
More informationOriginal paper. Abstract. Abdullah S. Asia 1*, Al-Mahdi A. Modar 2, Hadi M. Ali 3
Original paper Frequency Of Potential Adverse Effects Of A Semisynthetic Statin (Simvastatin) Compared To A Synthetic Statin (Atorvastatin) Used To Reduce Cardiovascular Risk For Patients In Basra 1*,
More informationA Review: Atherosclerosis & its treatment
73 Review Article A Review: Atherosclerosis & its treatment Yogesh K. Patil* Department of Pharmacology, Shree Mahavir Institute of Pharmacy, Nashik, Maharashtra, India *yogesh_kpatil85@yahoo.co.in ABSTRACT
More informationDiseases & Conditions
http://my.clevelandclinic.org Diseases & Conditions About Cholesterol-Lowering Drugs Some people have a genetic predisposition to high blood cholesterol levels. These people may need drug therapy in addition
More informationMedical evidence suggests that
COMBINATION THERAPY TO ACHIEVE LIPID GOALS David G. Robertson, MD* ABSTRACT Coronary heart disease (CHD) remains the leading cause of death in the United States despite recent advances in treatment and
More informationReview of guidelines for management of dyslipidemia in diabetic patients
2012 international Conference on Diabetes and metabolism (ICDM) Review of guidelines for management of dyslipidemia in diabetic patients Nan Hee Kim, MD, PhD Department of Internal Medicine, Korea University
More informationB. Patient has not reached the percentage reduction goal with statin therapy
Managing Cardiovascular Risk: The Importance of Lowering LDL Cholesterol and Reaching Treatment Goals for LDL Cholesterol The Role of the Pharmacist Learning Objectives 1. Review the role of lipid levels
More informationCoronary heart disease is the leading cause of death in
PHARMACOLOGY NOTES Ezetimibe (Zetia): a new type of lipid-lowering agent JIGNA PATEL, PHARMD CANDIDATE, VALERIE SHEEHAN, PHARMD, AND CHERYLE GURK-TURNER, RPH Coronary heart disease is the leading cause
More informationElements for a Public Summary
Rosuvastatin Stada 5 mg film-coated tablets Rosuvastatin Stada 10 mg film-coated tablets Rosuvastatin Stada 20 mg film-coated tablets Rosuvastatin Stada 40 mg film-coated tablets 25.8.2014, V1.1 PUBLIC
More informationHow to Handle Statin Intolerance in the High Risk Patient
How to Handle Statin Intolerance in the High Risk Patient Thomas D. Conley, MD FACC FSCAI Disclosures: None 1 Definition of High Risk Primary Prevention ASCVD Risk Calculator Adults >21 yrs, LDL 190 mg/dl
More informationNon-Statin Lipid-Lowering Agents M Holler - Last updated: 10/2016
Drug/Class Cholestyramine (Questran) Bile acid sequestrant Generic? Lipid Effects Y/N (monotherapy) Y LDL : 9% (4 g to 8 ; 21% (16 g to 20 ; 23% to 28% (>20 HDL : 4% to 8% (16 to 24 TG : 11% to 28% (4
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationCHOLESTAGEL 625 mg Genzyme
CHOLESTAGEL 625 mg Genzyme 1. NAME OF THE MEDICINAL PRODUCT Cholestagel 625 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 625 mg colesevelam hydrochloride (hereafter
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationHighlights of the new blood pressure and cholesterol guidelines: A whole new philosophy. Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM
Highlights of the new blood pressure and cholesterol guidelines: A whole new philosophy Jeremy L. Johnson, PharmD, BCACP, CDE, BC-ADM OSHP 2014 Annual Meeting Oklahoma City, OK April 4, 2014 1 Objectives
More informationSupplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction
Supplement: Tables Supplement Table 1. Study Eligibility Criteria Supplement Table 2. Categorization of Statin Intensity Based on Potential Low-Density Lipoprotein Cholesterol Reduction Supplement Table
More informationLipid Panel Management Refresher Course for the Family Physician
Lipid Panel Management Refresher Course for the Family Physician Objectives Understand the evidence that was evaluated to develop the 2013 ACC/AHA guidelines Discuss the utility and accuracy of the new
More informationLipid Management: A Case-Based Approach. Overview. Simple Lipid Therapy Approach. Patients have lipid disorders of:
Lipid Management: A Case-Based Approach Patrick E. McBride, M.D., M.P.H. Professor of Medicine, Cardiovascular Medicine Associate Director, Preventive Cardiology Program UW School of Medicine and Public
More information2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: Choline Fenofibrate (335) Name of Active Ingredient:
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationDyslipidemia. (Med-341)
Dyslipidemia (Med-341) Anwar A Jammah, MD, FRCPC, FACP, CCD, ECNU. Associate Professor of Medicine Consultant Medicine, Endocrinology, Thyroid Oncology Department of Medicine, King Saud University The
More informationComprehensive Treatment for Dyslipidemias. Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium
Comprehensive Treatment for Dyslipidemias Eric L. Pacini, MD Oregon Cardiology 2012 Cardiovascular Symposium Primary Prevention 41 y/o healthy male No Medications Normal BP, Glucose and BMI Social History:
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationThreshold Level or Not for Low-Density Lipoprotein Cholesterol
... SYMPOSIA PROCEEDINGS... Threshold Level or Not for Low-Density Lipoprotein Cholesterol Based on a debate between Philip J. Barter, MD, PhD, FRACP, and Frank M. Sacks, MD Debate Summary As drugs, such
More informationDeath is inevitable but premature death is not. Sir Richard Doll
Welcome to the Diabetes Care for You webinar Please log onto the conference call so you can hear our presenter From any SCFT Cisco phone dial 800800 From a mobile phone or any other phone dial 01273 242
More informationJAMA. 2011;305(24): Nora A. Kalagi, MSc
JAMA. 2011;305(24):2556-2564 By Nora A. Kalagi, MSc Cardiovascular disease (CVD) is the number one cause of mortality and morbidity world wide Reducing high blood cholesterol which is a risk factor for
More informationLipids & Hypertension Update
Lipids & Hypertension Update No financial disclosures Michael W. Cullen, MD, FACC Senior Associate Consultant, Assistant Professor of Medicine Mayo Clinic Department of Cardiovascular Diseases 34 th Annual
More information2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March Crowne Plaza, Dublin
2017 Cardiovascular Summit for Primary Care Thursday 30th & Friday 31st March 2017 - Crowne Plaza, Dublin 2016 ESC Guidelines on Cardiovascular Risk and elevated lipids Carlos Brotons Sardenya Primary
More information2013 Cholesterol Guidelines. Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc.
2013 Cholesterol Guidelines Anna Broz MSN, RN, CNP, AACC Cer=fied Adult Nurse Prac==oner North Ohio Heart, Inc. Disclosures Speaker Gilead Sciences NHLBI Charge to the Expert Panel Evaluate higher quality
More informationStatin Intolerance. Jason Evanchan DO, FACC April 20 th, 2018
Statin Intolerance 2 nd Annual CV Course for Trainees and Early Career Physicians: Current Concepts in the Diagnosis and Management of Coronary Artery Disease Jason Evanchan DO, FACC April 20 th, 2018
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationLong-Term Complications of Diabetes Mellitus Macrovascular Complication
Long-Term Complications of Diabetes Mellitus Macrovascular Complication Sung Hee Choi MD, PhD Professor, Seoul National University College of Medicine, SNUBH, Bundang Hospital Diabetes = CVD equivalent
More informationhyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER
Management of hyperlipidemia in CKD DR MOJGAN MORTAZAVI ASSOCIATE PROFESSOR OF NEPHROLOGY ISFAHAN KIDNEY DISEASES RESEARCH CENTER Background on Dyslipidemia in CKD In advanced chronic kidney disease (CKD),
More informationAn update on lipidology and cardiovascular risk management. Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine
An update on lipidology and cardiovascular risk management Lipids, Metabolism & Vascular Risk Section - Royal Society of Medicine National and international lipid modification guidelines: A critical appraisal
More informationFinancial Disclosures
1 Lipids in Type 2 Diabetes July 20, 2013 Abhimanyu Garg, M.D. Professor of Internal Medicine Chief, Division of Nutrition and Metabolic Diseases Distinguished Chair in Human Nutrition Research UT Southwestern
More information(For National Authority Use Only) Name of Study Drug: to Part of Dossier:
2.0 Synopsis Abbott Laboratories Individual Study Table Referring to Part of Dossier: (For National Authority Use Only) Name of Study Drug: Volume: ABT-335 Name of Active Ingredient: Page: ABT-335, A-7770335.115
More informationNearly 62 million people in the. ... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III
... REPORTS... New Therapeutic Options in the National Cholesterol Education Program Adult Treatment Panel III Robert L. Talbert, PharmD Abstract Coronary heart disease (CHD) is a common, costly, and undertreated
More information2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD
2013 ACC AHA LIPID GUIDELINE JAY S. FONTE, MD How do you interpret my blood test results? What are our targets for these tests? Before the ACC/AHA Lipid Guidelines A1c:
More informationNICE QIPP about Lipitor. Robert Trotter. Clinical Effectiveness Consultant
NICE QIPP about Lipitor Robert Trotter Clinical Effectiveness Consultant LIP2894c Date of preparation: April 2009 Prescribing information for atorvastatin is available on the last slide Roadmap Background
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationMarshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona,
Marshall Tulloch-Reid, MD, MPhil, DSc, FACE Epidemiology Research Unit Tropical Medicine Research Institute The University of the West Indies, Mona, Jamaica At the end of this presentation the participant
More informationCVD Risk Assessment. Lipid Management in Women: Lessons Learned. Conflict of Interest Disclosure
Lipid Management in Women: Lessons Learned Conflict of Interest Disclosure Emma A. Meagher, MD has no conflicts to disclose Emma A. Meagher, MD Associate Professor, Medicine and Pharmacology University
More informationManagement of Hyperlipidaemia in General Practice
Management of Hyperlipidaemia in General Practice Pages with reference to book, From 285 To 287 Waris Qidwai ( Family Medicine Division, Department of Community Health Sciences, The Aga Khan University,
More information4/24/15. AHA/ACC 2013 Guideline Key Points
Review of the ACC/AHA 2013 Guidelines Anita Ralstin, MS, CNS, CNP Next Step Health Consultant, LLC 1! Discuss the rationale for the change in lipid guidelines and how that affects the decision to implement
More informationDrug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin
Drug Class Review HMG-CoA Reductase Inhibitors (Statins) and Fixed-dose Combination Products Containing a Statin Final Report Update 5 November 2009 This report reviews information about the comparative
More informationYoung high risk patients the role of statins Dr. Mohamed Jeilan
Young high risk patients the role of statins Dr. Mohamed Jeilan KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Consensus and Controversy in Diabetic Dyslipidemia
Consensus and Controversy in Diabetes and Dyslipidemia Om P. Ganda MD Director, Lipid Clinic Joslin diabetes Center Boston, MA, USA CVD Outcomes in DM vs non- DM 102 Prospective studies; 698, 782 people,
More informationTreating Hyperlipidemias in Adults. Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC
Treating Hyperlipidemias in Adults Lisa R. Tannock MD Division of Endocrinology and Molecular Medicine, University of Kentucky Lexington KY VAMC Disclosures Conflicts: None Talk will address off-label
More informationSafety profile of atorvastatin-treated patients with low LDL-cholesterol levels
Atherosclerosis 149 (2000) 123 129 www.elsevier.com/locate/atherosclerosis Safety profile of atorvastatin-treated patients with low LDL-cholesterol levels Rebecca G. Bakker-Arkema *, James W. Nawrocki,
More information... CPE/CNE QUIZ... CPE/CNE QUESTIONS
CPE/CNE QUESTIONS Continuing Pharmacy Education Accreditation The Virginia Council on Pharmaceutical Education is approved by the American Council on Pharmaceutical Education as a provider of continuing
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS: WHERE DO WE STAND WITH THE NEW PRACTICE GUIDELINES? Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Disclosure No relevant financial relationships
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationSOLVAY GROUP London Morning Meeting. June 26, 2009
SOLVAY GROUP London Morning Meeting June 2, 9 1 Our fenofibrate franchise Klaus Kirchgassler, MD Sr VP Solvay Pharmaceuticals 2 Summary of lipid lowering market performance in Value Growth vs. previous
More informationFenofibrate interaction
Search Query (DRUGGENERICNAME = Avandia ) AND (RECORDTYPE = Case Report ) 1 Documents Exported 1. Fenofibrate interaction First report of an interaction with concomitant rosiglitazone leading to muscular
More informationModern Lipid Management:
Modern Lipid Management: New Drugs, New Targets, New Hope Kirk U. Knowlton, M.D Director of Cardiovascular Research Co Chief of Cardiology Why lower LDL C in those without evidence of CAD (primary prevention)
More informationDyslipidemia and HIV NORTHWEST AIDS EDUCATION AND TRAINING CENTER
NORTHWEST AIDS EDUCATION AND TRAINING CENTER Dyslipidemia and HIV Heidi Crane, MD, MPH Madison Metabolic Clinic Associate Professor UW Department of Medicine Presentation prepared by: Heidi Crane, MD,
More informationTreating dyslipidemia
Treating dyslipidemia in patients with type 2 diabetes mellitus 18 The Nurse Practitioner Vol. 40, No. 18 www.tnpj.com 2.0 CONTACT HOURS 1.0 CONTACT HOURS Abstract: Type 2 diabetes mellitus is associated
More informationPharmacy Drug Class Review
Pharmacy Drug Class Review January 22, 2014 Authored By: Christina Manciocchi, Pharm.D. BCACP Disclaimer: Specific agents may have variations Edited By: Richard J. Kraft, Pharm.D.BCPS NEW CHOLESTEROL GUIDELINES
More informationDisclosures. Choosing a Statin/New Therapies. Case. How else would you do to treat him? LDL-C Reduction with Different Statin Strategies
Disclosures I have no disclosures relevant to this talk Choosing a Statin/New Therapies Aryan Aiyer, MD Assistant Professor of Medicine University of Pittsburgh School of Medicine UPMC Heart and Vascular
More informationDiabetic Dyslipidemia
Diabetic Dyslipidemia Dr R V S N Sarma, M.D., (Internal Medicine), M.Sc., (Canada), Consultant Physician Cardiovascular disease (CVD) is a significant cause of illness, disability, and death among individuals
More informationBehind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL
Behind LDL: The Metabolism of ApoB, the Essential Apolipoprotein in LDL and VLDL Sung-Joon Lee, PhD Division of Food Science Institute of Biomedical Science and Safety Korea University Composition of Lipoproteins:
More informationAccelerated atherosclerosis begins years prior to the diagnosis of diabetes
Joslin Diabetes Forum 211: Optimizing Care for the Practicing Clinician Risk for atherosclerosis is 2 4 times greater in patients with diabetes CVD accounts for 65% of diabetic mortality >5% of patients
More informationCoronary Artery Disease Clinical Practice Guidelines
Coronary Artery Disease Clinical Practice Guidelines Guidelines are systematically developed statements to assist patients and providers in choosing appropriate healthcare for specific clinical conditions.
More informationUniv.-Doz. Prof. Dr. W. Renner
Pharmacogenetics of statin-inducedinduced myopathies Wilfried Renner Medical University Graz Clinical Institute of Medical and Chemical Laboratory Diagnostics It started with a fungus 1973: Isolation of
More informationIntroduction. Objective. Critical Questions Addressed
Introduction Objective To provide a strong evidence-based foundation for the treatment of cholesterol for the primary and secondary prevention of ASCVD in women and men Critical Questions Addressed CQ1:
More informationLandmark Clinical Trials.
Landmark Clinical Trials 1 Learning Objectives Discuss clinical trials and their role in lipid and lipoprotein treatment in cardiovascular prevention. Review the clinical trials of lipid-altering drug
More informationReducing low-density lipoprotein cholesterol treating to target and meeting new European goals
European Heart Journal Supplements (2004) 6 (Supplement A), A12 A18 Reducing low-density lipoprotein cholesterol treating to target and meeting new European goals University of Sydney, Sydney, NSW, Australia
More information